据《彭博通讯社》引述知情人士指,信达生物(01801.HK) 在与一家顾问机构合作,评估全球制药公司对其自研首创PD-1/IL-2 Alpha-bias双特异性抗体融合蛋白产品“IBI363”的兴趣,预期通过向其他药厂授权该产品可推进研发及商业化进程。若达成授权协议,预期信达生物可获得前期付款及里程碑款项。消息指审议仍处于初步阶段。信达生物早前指,正在中国、美国、澳洲开展临床研究探索IBI363在...
Source Link据《彭博通讯社》引述知情人士指,信达生物(01801.HK) 在与一家顾问机构合作,评估全球制药公司对其自研首创PD-1/IL-2 Alpha-bias双特异性抗体融合蛋白产品“IBI363”的兴趣,预期通过向其他药厂授权该产品可推进研发及商业化进程。若达成授权协议,预期信达生物可获得前期付款及里程碑款项。消息指审议仍处于初步阶段。信达生物早前指,正在中国、美国、澳洲开展临床研究探索IBI363在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.